Seeking Alpha

ImmunoGen stops Phase II study of lung-cancer treatment

  • ImmunoGen (IMGN) has halted a Phase II trial of its IMGN901 drug in patients with small-cell lung cancer, due to too many infections and infection-related deaths.
  • The Data Monitoring Committee of the study concluded that the use of IMGN901 was unlikely to demonstrate a sufficient improvement in progression-free survival. (PR)
  • However, ImmunoGen has initiated Phase I testing of IMGN289, a potential treatment for lung, head and neck tumors. (PR)
  • Shares are -9.4%.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector